You are here

Merck KGaA

Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug

Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug

Pharmaforum

non-small cell lung cancer

Flag link:

Shifting focus to oncology, GSK recruits a cancer vet as new chief of US pharmaceuticals — adding another woman to the top ranks of biopharma

Shifting focus to oncology, GSK recruits a cancer vet as new chief of US pharmaceuticals — adding another woman to the top ranks of biopharma

Endpoints

Maya Martinez-Davis

Flag link:

Tackling the remaining challenges of multiple sclerosis

Tackling the remaining challenges of multiple sclerosis

Pharmaforum

multiple sclerosis

Flag link:

Startup offering free DNA sequencing signs first pharma sponsor

Startup offering free DNA sequencing signs first pharma sponsor

Stat

Nebula Genomics

Flag link:

Merck and Pfizer’s Bavencio approved for renal cell carcinoma

Merck and Pfizer’s Bavencio approved for renal cell carcinoma

Pharmaforum

advanced renal cell carcinoma

Flag link:

Merck KGaA retools F-star pact, walks away from lead PD-L1 drug

Merck KGaA retools F-star pact, walks away from lead PD-L1 drug

Fierce Biotech

bispecific antibodies

Flag link:

German Merck finally gets yes for MS drug Mavenclad

German Merck finally gets yes for MS drug Mavenclad

Biopharma Dive

multiple sclerosis

Flag link:

Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making

Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making

Endpoints

multiple sclerosis

Flag link:

Merck KGaA injecting €150M into biologics site where it makes immunotherapies

Merck KGaA injecting €150M into biologics site where it makes immunotherapies

Fierce Pharma

drug manufacturing

Flag link:

Merck KGaA investing €1B at headquarters site as part of 5-year work agreement

Merck KGaA investing €1B at headquarters site as part of 5-year work agreement

Fierce Pharma

Flag link:

Pfizer, Merck KGaA throw in the towel on another Bavencio PhIII as once bright hopes shrivel fast

Pfizer, Merck KGaA throw in the towel on another Bavencio PhIII as once bright hopes shrivel fast

Endpoints

Flag link:

Merck KGaA signs another AI deal

Merck KGaA signs another AI deal

Pharmaforum

artificial intelligence

Flag link:

Merck KGaA admits to ‘challenging’ 2018, as currencies hit sales

Merck KGaA admits to ‘challenging’ 2018, as currencies hit sales

Pharmaforum

Flag link:

After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck

After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck

Endpoints

Flag link:

Forget the suggestion box. Merck KGaA puts employee ideas on a TED stage

Forget the suggestion box. Merck KGaA puts employee ideas on a TED stage

Fierce Pharma

pharma employees

Flag link:

Merck KGaA signs China digital health deal with Tencent

Merck KGaA signs China digital health deal with Tencent

Pharmaforum

digital healthcare

artificial intelligence

Flag link:

Vertex sharpens focus on gene-editing in licensing deal with Merck KGaA

Vertex sharpens focus on gene-editing in licensing deal with Merck KGaA

Endpoints

Vertex Pharmaceuticals

Flag link:

Bavencio fails second ovarian cancer Phase III trial

Bavencio fails second ovarian cancer Phase III trial

BioCentury

Flag link:

Merck KGaA hands off its CAR-T R&D operations to Intrexon in $175M deal

Merck KGaA hands off its CAR-T R&D operations to Intrexon in $175M deal

Endpoints

Flag link:

Merck's Keytruda puts heat on Pfizer, Merck KGaA's Bavencio with new Merkel cell OK

Merck's Keytruda puts heat on Pfizer, Merck KGaA's Bavencio with new Merkel cell OK

Fierce Pharma

Merkel cell carcinoma

Flag link:

Pages